<DOC>
	<DOCNO>NCT02531126</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy RPC1063 patient diagnose moderate severe ulcerative colitis .</brief_summary>
	<brief_title>Open-Label Extension RPC1063 Therapy Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description>The trial open label extension study . Eligible patient RPC01-3101 trial diagnose moderate severe ulcerative colitis enrol receive study medication 5 year market approval .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Previous participation trial RPC1063 ulcerative colitis ( UC ) may benefit continued treatment Require initiation therapy use treatment UC Pregnant , lactating , positive serum pregnancy test Have clinically relevant cardiovascular condition relevant disease would put patient risk make interpretation trial difficult</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>